Cargando…
Biomarkers Associated with Death After Initiating Treatment for Tuberculosis and HIV in Patients with Very Low CD4 Cells
BACKGROUND: The risk of short-term death for treatment naive patients dually infected with Myco-bacterium tuberculosis and HIV may be reduced by early anti-retroviral therapy. Of those dying, mechanisms responsible for fatal outcomes are unclear. We hypothesized that greater malnutrition and/or infl...
Autores principales: | Sattler, Fred R., Chelliah, Daniel, Wu, Xingye, Sanchez, Alejandro, Kendall, Michelle A., Hogg, Evelyn, Lagat, David, Lalloo, Umesh, Veloso, Valdilea, Havlir, Diane V., Landay, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pathogens and Immunity
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951172/ https://www.ncbi.nlm.nih.gov/pubmed/29770360 http://dx.doi.org/10.20411/pai.v3i1.235 |
Ejemplares similares
-
Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings
por: Gupta, Amita, et al.
Publicado: (2022) -
HIV and tuberculosis – science and implementation to turn the tide and reduce deaths
por: Harries, Anthony D, et al.
Publicado: (2012) -
Impact of Larger Sputum Volume on Xpert(®) MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis
por: Badal-Faesen, Sharlaa, et al.
Publicado: (2017) -
The science of rapid start—From the when to the how of antiretroviral initiation
por: Geng, Elvin H., et al.
Publicado: (2017) -
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)—report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group
por: Lalloo, Umesh G., et al.
Publicado: (2023)